Drugs / Perflutren lipid
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01751529 | May 2013 → Nov 2015 | kidney cancer | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06654804 | Sep 2023 → Sep 2027 expected | spinal cord injury | University of Washington | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07225114 Background | Nov 2025 → Dec 2028 expected | breast cancer, kidney neoplasm, liver and intrahepatic bile duct neoplasm | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Perflutren lipid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06654804 ↗ |
| Modality | Diagnostic / imaging agent | “using microbubble contrast agent (perflutren lipid; Definity®)” NCT01751529 ↗ |
| Route | Intravenous | “A bolus IV injection of Perflutren lipid contrast agent will be given.” NCT06654804 ↗ |